Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of INCB161734 in Severe Renal Impairment and ESRD
NCT07854249Phase 1Not yet recruiting
- Sponsor
- Incyte
- Start
- Oct 2026
- Primary completion
- Mar 2027
01
Overview
Phase 1, open-label trial of INCB161734 in cancer (2 arms), sponsored by Incyte. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
INCB161734
03
Conditions
cancer
Beyond the preview
Go deeper on NCT07854249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07854249.